Table 2 Incidence of primary endpoints in rheumatoid arthritis patients assigned to PPSV23 or placebo
|  | Vaccine group (n = 464) |  | Placebo group (n = 436) |  |  |
|---|---|---|---|---|---|
Incidence rate per 1000 patient-years (n) | 95% CI | Incidence rate per 1000 patient-years (n) | 95% CI | P value | |
Pneumococcal pneumonia | 2.6 (2) | 0.7–9.5 | 1.4 (1) | 0.3–8.0 | 0.523 |
Nonpneumococcal pneumonia | 19.6 (15) | 11.9–32.3 | 19.9 (14) | 11.9–33.4 | 0.985 |
All-cause pneumonia | 22.2 (17) | 13.9–35.6 | 21.3 (15) | 12.9–35.2 | 0.856 |